Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer

MET amplification is rare in treatment-naïve metastatic colorectal cancer (CRC) tumors, but can emerge as a mechanism of resistance to anti-EGFR therapies. Preclinical and clinical data suggest that patients with MET amplified tumors benefit from MET-targeted therapy. Cabozantinib is an inhibitor of...

Full description

Bibliographic Details
Main Authors: Jingquan Jia, Michael A. Morse, Rebecca J. Nagy, Richard B. Lanman, John H. Strickler
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Oncology
Subjects:
MET amplification
metastatic colorectal cancer
cabozantinib
cell-free DNA
ctDNA
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00305/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00305/full

Similar Items